GlassScriptPhysician profile
Angela D Kaminsky
NPI 1811349806
$3,945.59
in general payments reported to CMS, 2019-2025
21 companies · $471 in 2025
The $471 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $357 · 2021: $1,595 · 2022: $418 · 2023: $139 · 2024: $770 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $1,514.04 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $697.81 | 2022-2025 | Infuse Multifocal, Infuse, Biotrue One Day |
| Sight Sciences, INC. | $367.95 | 2022-2025 | Omni Surgical System, Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $207.35 | 2020-2023 | Tecnis Iol |
| Allergan, INC. | $148.82 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.38 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $101.71 | 2019 | |
| Biotissue Holdings INC. | $92.95 | 2021-2025 | |
| Notal Vision, INC. | $89.73 | 2024 | Foresee Home |
| Alcon Vision LLC | $82.42 | 2024 | Clareon |
| Mallinckrodt Hospital Products INC. | $81.29 | 2023-2024 | Acthar |
| Dompe US, INC. | $80.14 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $72.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.05 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $49.97 | 2019-2025 | Cequa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $46.74 | 2022-2024 | Ryzumvi, Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $44.96 | 2024-2025 | Xdemvy |
| Amgen INC. | $28.42 | 2025 | Tepezza |
| Abbvie INC. | $23.38 | 2022 | |
| Astellas Pharma US INC | $21.12 | 2024 | Izervay |
| Harrow Eye, LLC | $15.81 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Kaminsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.